Cariprazine
Indication
Treatment of schizophrenia in adult patients
Amber level 1
Brand:
Reagila ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
Cariprazine is recommended as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.
-
Cariprazine is suitable for prescribing in primary care following recommendation or initiation by a specialist.
-
Full prior agreement about patient’s on-going care must be reached under a shared care agreement.
Recommendation
LSCMMG Recommendation:
Amber level 1
Reason for decision:
Shared care required
Supporting documents: